



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

### Complete if Known

Application Number	09/978,333
Filing Date	October 15, 2001
First Named Inventor	Peter M. Glazer
Group Art Unit	1655
Examiner Name	
Attorney Docket Number	YU 132 (OCR 653)

TECH CENTER 1600/2900

AUG 09 2002

RECEIVED

### OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
CM		BAUMANN, et al., "Role of the human RAD51 protein in homologous recombination and double-stranded-break repair," <i>Trends Biochem Sci</i> 23(7):247-251 (1998).	✓
		BEAL, et al., "Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation," <i>Science</i> 251:1360-1363 (1991).	✓
		BEAL, et al., "The influence of single base triplet changes on the stability of Pur-Pur-Pyr triple helix determined by affinity cleaving," <i>Nuc. Acids Res.</i> 20(11):2773-2776 (1992).	✓
		BLUME, et al., "Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," <i>Nucleic Acids Res.</i> 20:1777-1784 (1992).	✓
		BRENNEMAN, et al., "Stimulation of intrachromosomal homologous recombination in human cells by electroporation with site-specific endonucleases," <i>Proc. Natl. Acad. Sci. USA</i> 93(8): 3608-12 (1996).	✓
		CAMPBELL, et al., "Homologous recombination involving small single-stranded oligonucleotides in human cells," <i>New Biol.</i> 1(2):223-7 (1989).	✓
		CAPECCHI, "Altering the genome by homologous recombination," <i>Science</i> 244(4910): 1288-1292 (1989).	✓
		CHAN, et al., "Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide," <i>J. Biol. Chem.</i> 274(17): 11541-11548 (1999).	✓
		COONEY, et al., "Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro," <i>Science</i> 241: 456-459 (1988).	✓
		DURLAND, et al., "Binding of triple helix forming oligonucleotides to sites in gene promoters," <i>Biochemistry</i> 30:9246-9255 (1991).	✓

Examiner's Signature	<i>Chris S</i>	Date Considered	9-20-01
----------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Use as many sheets as necessary)		Application Number	09/978,333
		Filing Date	October 15, 2001
		First Named Inventor	Peter M. Glazer
		Group Art Unit	1655
		Examiner Name	
		Attorney Docket Number	YU 132 (OCR 653)



OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
Cy		DUVAL-VALENTIN, et al., "Specific inhibition of transcription by triple helix-forming oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 89:504-508 (1992).	
		FARUQI, et al., "Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent pathway," <i>Mol Cell Biol</i> 20(3): 990-1000 (2000).	
		FELSENFELD, et al., "Formation of a three-stranded polynucleotide molecule," <i>J. Am. Chem. Soc.</i> 79:2023-2024 (1957).	
		FRANCOIS, et al., "Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate," <i>Proc. Natl. Acad. Sci. USA</i> 86:9702-9706 (1989).	
		GLAZER, et al., "DNA mismatch repair detected in human cell extracts," <i>Mol. Cell. Biol.</i> 7:218-224 (1987).	
		GONCZ, et al., "Site-directed alteration of genomic DNA by small-fragment homologous replacement," <i>Methods Mol. Biol.</i> 133:85-93 (2000).	
		GRIGORIEV, et al., "A triple helix-forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NF kappa B binding to interleukin-2 receptor alpha-regulatory sequence," <i>J. of Biological Chem.</i> 267:3389-3395 (1992).	
		HANSON, et al., "Analysis of biological selections for high-efficiency gene targeting," <i>Mol. Cell. Biol.</i> 15(1):45-51 (1995).	
		HAYRE, et al., "Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide," <i>J. Virology</i> 67:7324-7331 (1993).	
		HELENE, "Sequence-selective recognition and cleavage of double-helical DNA," <i>Curr. Opinion Biotechnology</i> 4:29-36 (1993).	

Examiner's Signature	<i>Coyne</i>	Date Considered	9-20-01
----------------------	--------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

AUG 09 2002

TECH CENTER 1600/200

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	09/978,333
		Filing Date	October 15, 2001
		First Named Inventor	Peter M. Glazer
		Group Art Unit	1655
		Examiner Name	
		Attorney Docket Number	YU 132 (OCR 653)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
Ch		ITO, et al., "Sequence-specific DNA purification by triplex affinity capture," <i>Proc. Natl. Acad. Sci. USA</i> 89:495-498 (1992).	✓
		JAKUBCZAK, et al., "Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target," <i>Proc. Natl. Acad. Sci. USA</i> 93:9073-9078 (1996).	✓
		JONES, et al., "Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA," <i>Biochemistry</i> 32:12096-12104 (1993).	✓
		LETAI, et al., "Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns," <i>Biochemistry</i> 27:9108-9112 (1988).	✓
		LIN, et al., "Extrachromosomal recombination in mammalian cells as studied with single- and double-stranded DNA substrates," <i>Mol. Cell Biol</i> 7(1):129-140 (1987).	✓
		LIN, et al., "Use of EDTA derivatization to characterize interactions between oligodeoxyribonucleoside methylenephosphonates and nucleic acids," <i>Biochemistry</i> 28:1054-1061 (1989).	✓
		LUO, et al., "High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides injected into mouse cells," <i>Proc. Natl. Acad. Sci. USA</i> 97(16): 9003-9008 (2000).	✓
		MAHER, et al., "Analysis of promoter-specific repression by triple-helical DNA complexes in a eukaryotic cell transcription system," <i>Biochemistry</i> 31:70-81 (1992).	✓
		MAHER, et al., "Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation," <i>Science</i> 255:725-728 (1992).	✓
		MERGNY, et al., "Sequence specificity in triple-helix formation: experimental and theoretical studies of the effect of mismatches on triplex stability," <i>Biochemistry</i> 30:9791-9798 (1991).	✓

Examiner's Signature	Chelso	Date Considered	9-20-01
----------------------	--------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+ RECEIVED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/978,333
		Filing Date	October 15, 2001
		First Named Inventor	Peter M. Glazer
		Group Art Unit	1655
		Examiner Name	
Attorney Docket Number	YU 132 (OCR 653)		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>4</sup>
On		MOSER, et al., "Sequence-specific cleavage of double helical DNA by triple helix formation," <i>Science</i> 238:645-650 (1987).	✓
		MYHR, "Validation studies with Muta Mouse: a transgenic mouse model for detecting mutations in vivo," <i>Environ. Mol. Mutagen</i> 18:308-315(1991).	✓
		NARAYANAN, et al., "Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2," <i>Proc. Natl. Acad. Sci. USA</i> 94:3122-3127 (1997).	✓
		ORSON, et al., "Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes," <i>Nucleic Acids Res.</i> 19:3435-3441 (1991).	✓
		PARK, et al., "Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins," <i>Proc. Natl. Acad. Sci. USA</i> 91:5017-5021 (1994).	✓
		PARRIS, et al., "Proximal and distal effects of sequence context on ultraviolet mutational hotspots in a shuttle vector replicated in xeroderma cells," <i>J Mol Biol.</i> 236:491-502 (1994).	✓
		PEI, et al., "Site-specific cleavage of duplex DNA by a semisynthetic nuclease via triple-helix formation," <i>Proc. Natl. Acad. Sci. USA</i> 87:9858-9862 (1990).	✓
		PERROUALT, et al., "Sequence-specific artificial photo-induced endonucleases based on triple helix-forming oligonucleotides," <i>Nature</i> 344:358-360 (1990).	✓
		POSTEL, et al., "Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels," <i>Proc. Natl. Acad. Sci. USA</i> 88:8227-8231 (1991).	✓
		POSVIC, et al., "Sequence-Specific Alkylation of Double-Helix DNA by Oligonucleotide-Directed Triple-Helix Formation," <i>J. Am. Chem Soc.</i> 112:9428-9430 (1990).	✓

Examiner's Signature		Date Considered	9-20-04
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



## Complete if Known

Application Number	09/978,333
Filing Date	October 15, 2001
First Named Inventor	Peter M. Glazer
Group Art Unit	1655
Examiner Name	
Attorney Docket Number	YU 132 (OCR 653)

**RECEIVED**  
 AUG 09 2002  
 TECH CENTER 1600/2800

Sheet	1	of	7
-------	---	----	---

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
CM		PRASEUTH, <i>et al.</i> , "Sequence-specific binding and photocrosslinking of alpha and beta oligodeoxynucleotides to the major groove of DNA via triple-helix formation," <i>Proc. Natl. Acad. Sci. USA</i> 85:1349-1353 (1988).	
		REARDON, <i>et al.</i> , "Removal of psoralen monoadducts and crosslinks by human cell free extracts," <i>Nucleic Acids Res.</i> 19:4623-4629 (1991).	
		SAMBROOK, <i>et al.</i> , MOLECULAR CLONING: A LABORATORY MANUAL, second edition, Cold Spring Harbor Laboratory Press, New York (1990).	
		SANCAR, "DNA excision repair," <i>Annu. Rev. Biochem.</i> 65:43-81 (1996).	
		SHIVJI, <i>et al.</i> , "Proliferating cell nuclear antigen is required for DNA excision repair," <i>Cell</i> 69: 367-374 (1992).	
		SIBGHAT-ULLAH, <i>et al.</i> , "Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract," <i>Nucleic Acids Res.</i> 17:4471-4484 (1989).	
		STROBEL, <i>et al.</i> , "Site-specific cleavage of human chromosome 4 mediated by triple-helix formation," <i>Science</i> 254:1639-1642 (1991).	
		SUNG, <i>et al.</i> , "Recombination factors of <i>Saccharomyces cerevisiae</i> ," <i>Mutat Res</i> 451:257-75 (2000).	
		TAKASUGI, <i>et al.</i> , "Sequence-specific photo-induced cross-linking of the two strands of double-helical DNA by a psoralen covalently linked to a triple helix-forming oligonucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 88:5602-5606 (1991).	
CM		THACKER, "A surfeit of RAD51-like genes?," <i>Trends Genet</i> 15(5):166-8 (1999).	

Examiner's Signature	<i>CMeyer</i>	Date Considered	9-20-04
----------------------	---------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	09/978,333
		Filing Date	October 15, 2001
		First Named Inventor	Peter M. Glazer
		Group Art Unit	1655
		Examiner Name	
Sheet 1 of 7	Attorney Docket Number	YU 132 (OCR 653)	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>4</sup>
CM		VASQUEZ, et al., "Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells," <i>Nucleic Acids Res.</i> 27:1176-1181 (1999).	/
		WANG, et al., "Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair," <i>Science</i> 271: 802-805 (1996).	/
		WANG, et al., "Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation," <i>Mol. Cell. Biol.</i> 15:1759-1768 (1995).	/
		WOOD, et al., "Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts," <i>Cell</i> 53:97-106 (1988).	/
CM		YOUNG, et al., "Triple helix formation inhibits transcription elongation in vitro," <i>Proc. Natl. Acad. Sci. USA</i> 88:10023-10026 (1991).	/

Examiner's Signature	<i>CM</i>	Date Considered	9-20-04
----------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.